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Abstract
Context—Precise subtype diagnosis of non–small cell lung carcinoma is increasingly relevant, 
based on the availability of subtype-specific therapies, such as bevacizumab and pemetrexed, and 
based on the subtype-specific prevalence of activating epidermal growth factor receptor mutations.
Objectives—To establish a baseline measure of inter-observer reproducibility for non–small cell 
lung carcinoma diagnoses with hematoxylin-eosin for the current 2004 World Health Organization 
classification, to estimate interobserver reproducibility for the therapeutically relevant squamous/
nonsquamous subsets, and to examine characteristics that improve interobserver reproducibility.
Design—Primary, resected lung cancer specimens were converted to digital (virtual) slides. 
Based on a single hematoxylin-eosin virtual slide, pathologists were asked to assign a diagnosis 
using the 2004 World Health Organization classification. Kappa statistics were calculated for each 
pathologist-pair for each slide and were summarized by classification scheme, pulmonary 
pathology expertise, diagnostic confidence, and neoplastic grade.
Results—The 12 pulmonary pathology experts and the 12 community pathologists each 
independently diagnosed 48 to 96 single hematoxylin-eosin digital slides derived from 96 cases of 
non–small cell lung carcinoma resection. Overall agreement improved with simplification from the 
comprehensive 44 World Health Organization diagnoses (κ = 0.25) to their 10 major header 
subtypes (κ = 0.48) and improved again with simplification into the therapeutically relevant 
squamous/nonsquamous dichotomy (κ = 0.55). Multivariate analysis showed that higher 
diagnostic agreement was associated with better differentiation, better slide quality, higher 
diagnostic confidence, similar years of pathology experience, and pulmonary pathology expertise.
Conclusions—These data define the baseline diagnostic agreement for hematoxylin-eosin 
diagnosis of non–small cell lung carcinoma, allowing future studies to test for improved diagnostic 
agreement with reflex ancillary tests.
The diagnosis of non–small cell lung carcinoma (NSCLC) histologic subtype is the current 
gold standard for appropriate selection of chemotherapy, affecting the safety of 
bevacizumab1 and the efficacy of pemetrexed.2 The efficacy of epidermal growth factor 
receptor (EGFR) tyrosine kinase inhibitors3 is higher in patients with activating EGFR gene 
mutations,4 present in 10% to 20% of lung adenocarcinoma (AD),5 but few or no lung 
squamous carcinoma (SC).6 Here, we estimate pathologists’ diagnostic agreement by 
measuring interobserver reproducibility (IOR) for hematoxylin-eosin (H&E) diagnosis of 
NSCLC subtypes in resected specimens using the 2004 World Health Organization 
classification (2004-WHO).7
Four WHO lung cancer classifications have been published: 1967,8 1982,9 1999,10 and 
2004.7 These classifications are based primarily on light microscopic evaluation of H&E-
stained sections from resected neoplasms. Incremental refinements between editions have 
included reclassification for some disease entities (eg, solid AD with mucin production), 
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recognition of new disease entities (eg, large cell neuroendocrine carcinoma), fine-tuning of 
diagnostic criteria, and correlation with clinical, radiographic, immunohistochemical, and 
molecular variables.
Diagnostic agreement can be estimated by measuring percentage agreement or by 
calculating a κ statistic, which accounts for chance agreement. The κ statistic ranges from 
complete disagreement (κ = −1.0) to complete agreement (κ = 1.0), with a target minimum 
for clinical testing of 0.7.11 Although the WHO classification system is complex, studies 
typically simplify categories.12–24 Four studies assessed H&E-only IOR for NSCLC. Using 
the 1967 WHO classification, Feinstein et al17 found 95% to 98% agreement for epidermoid 
and AD when well differentiated (WD), but only 58% to 60% agreement when poorly 
differentiated (PD). With the 1982 WHO classification, Hanai et al20 and Yamamoto et al24 
reported 77% to 100% and 97% to 98% agreement, respectively. Burnett et al12,13 reported 
κ = 0.28 to 0.30 for SC and AD with modest improvement when mucin stains were 
provided. Other IOR studies14,15,18,19,22 are not directly comparable to the current study 
because they mix H&E-only diagnoses with diagnoses using both H&E and mucin stains. 
Employing the 1999 WHO classification, Colby et al16 found dominant cell–type agreement 
in 74% to 82% of NSCLC/small cell lung cancer cases, with an overall κ of 0.65 to 0.74. No 
published IOR studies were found with the 2004-WHO classifications.
We designed this baseline study to measure the IOR (agreement) for diagnosis of resected 
NSCLC. Using the current 2004-WHO, we evaluated the IOR for the H&E diagnosis of 
NSCLC by comparing 24 pathologists’ diagnoses of representative, digital H&E slides from 
96 resected lung cancers. We report IORs for the complete 2004-WHO classification of 44 
diagnoses (44DC) and estimate IORs for the classification’s 10 major diagnostic categories 
(10DC) and the clinically relevant squamous/nonsquamous (SC/non-SC) classes (Table 1). 
We also report the effect of pathologists’ practice settings, expertise in lung pathology, years 
of experience, confidence in the H&E diagnosis, slide quality, and carcinoma grade on IOR. 
This study is the first, to our knowledge, to measure the agreement of NSCLC H&E 
diagnoses for the entire current 2004-WHO, to estimate IOR for the therapeutically relevant 
SC/non-SC classes, and to demonstrate the utility of digital slide review.
METHODS
Sample Selection and Study Population
Sequential, surgically resected, primary NSCLCs (n = 96) collected at the University of 
North Carolina (Chapel Hill) from 1997–2007 were identified. Single diagnostic blocks used 
in the original pathologic diagnosis were recut and stained with H&E and were scanned 
using an Aperio ScanScope slide scanner (Aperio Technologies, Vista, California) into 
virtual slides viewable at magnifications equivalent to ×2 to ×20 objectives (×40 magnifier). 
Snapshot jpeg images (×2 and ×20) were created from unselected, central areas of the virtual 
slides. Grades were based on the original pathologic diagnosis. Small cell lung cancer, 
metastases, and normal specimens were excluded.
Increasing the number of pathologists increases the generalizability of the conclusions, and 
increasing the number of reviewed slides decreases the standard error around the κ estimate 
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of IOR.25 To balance these considerations, we recruited 12 expert lung pathologists from the 
Pulmonary Pathology Society and 12 community pathologists. Each pathologist reviewed 
two random sets of 24 slides of the total 96 slides. Some pathologists elected to review all 96 
slides.
Survey Content
Using DVDs containing virtual slides and Internet-based snapshots, pathologists recorded 
their 2004-WHO diagnoses onto an Internet-based survey. Pathologists were free to base 
their diagnoses on the virtual slide and/or the snapshot images. For each slide, pathologists 
reported diagnosis, quality of slide image, diagnostic confidence, and any additional 
comments. Pathologists’ personal identifiers were removed by a designated data manager, 
but linked demographic information was retained, including years in practice and surgical 
pathology fellowship (yes/no), as well as whether the participant was an expert lung 
pathologist or a community pathologist. The study was approved by the University of North 
Carolina Institutional Review Board.
Statistical Methods
The Cohen26 simple κ statistic was used to measure agreement among the 222 pathologist-
pairs, from combinations of 24 pathologists. Pathologists’ 44DC were collapsed into 10 DC 
and then into SC/non-SC categories (Table 1).27
Bootstrap methods28,29 (including block bootstrapping) were used to calculate standard 
errors (standard deviations of the bootstrapped means), through which, 95% confidence 
intervals (CI) for the (weighted) mean κ statistics were calculated. Subgroup κ statistics 
were calculated along with their (bootstrap) 95% CI.
Exploratory analyses were performed using logistic regression modeling to examine possible 
associations of pathologist, slide, and tumor factors on the probability of agreement. The 
dependent variable of agreement on a diagnosis for a particular slide by a pathologist-pair 
was scored as agreement or disagreement. A c-index30 was used to measure and compare the 
levels of association for both univariable and multivariable models. The covariates that were 
evaluated relating to the pathologists included expertise, practice setting, and years of 
diagnostic experience (both the sum of their combined experience, and the absolute values 
of the difference in their years of experience). We distinguished between tumor factors 
(inherent to the entire case as diagnosed by the original pathologist) and slide factors 
(inherent to the image being considered). Tumor factor covariates included pathologic 
diagnosis and original neoplastic grade. Slide factor covariates included confidence in 
diagnosis and image quality. In our logistic regression analyses, we dichotomized diagnosis 
as SC versus non-SC, grade as WD versus moderately differentiated (MD) versus PD, and 
confidence as high or not high. Because of the exploratory nature of the analysis, we did not 
adjust for the dependencies among slides and pathologists. Odds ratios with 95% CIs are 
given for these covariates of interest (Table 4).
Analyses were performed using both SAS (Version 9.2; SAS Institute, Inc, Cary, North 
Carolina) and R statistical software (R Development Core Team 2008).31
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Twelve of 13 expert lung pathologists (92%) and 12 of 13 community pathologists (92%) 
agreed to participate in the study. A surgical pathology fellowship had been completed by 16 
of 24 pathologists (67%). A median of 17 years (range, 1–36 years) of posttraining 
experience was reported (Table 2). Based on the 24 study pathologists reviewing random 
allocations of 48 to 96 slides, a comprehensive 1:1 matching of pathologists’ pairwise 
agreements resulted in a total of 222 unique “pathologist-pairs” and 7130 unique slide 
viewings (“slide-pairs”) reviewed by the pathologist-pairs. Slide-pairs (2 pathologists’ 
diagnoses of a single slide) formed the fundamental unit by which we measured agreement.
All virtual slides contained cancer. All (96 of 96; 100%) low-power and 94% (90 of 96) of 
high-power jpeg snapshot images contained representative fields of the same neoplasm. Six 
percent (6 of 96) of the high-power jpeg snapshot images did not contain representative 
fields of the neoplasm seen in the low-power jpeg snapshot image. The IORs for 
pathologists who used primarily jpegs or both are similar with or without elimination of the 
6 cases with nonrepresentative high-power jpeg images.
Four out of 24 pathologists (17%) experienced technical challenges in use of the large DVD 
virtual slide files and retrospectively reported using jpegs exclusively or a mixture of jpegs 
and DVDs. The IORs for pathologists who primarily used DVDs were similar to those who 
used primarily jpegs or both versions (data not shown).
On average, pathologists rated 91% of the diagnostic images of sufficient quality for 
diagnosis, with little agreement on which slides were of low quality. Quality was uniformly 
scored as acceptable in 37 of 96 (39%), with an additional 32 slides (33%) receiving only 
one unacceptable quality rating. Pathologists assigned confidence in their diagnoses as 
follows: high, 52%; moderate, 40%; and poor, 8% (Table 2).
The distribution of the original and study diagnoses were AD, 35% and 36%; SC, 35% and 
31%; adenosquamous, 13% and 3%; large cell, 9% and 17%; miscellaneous, 6% and 7%; 
sarcomatoid carcinoma, 1% and 4%; and carcinoid, 1% and 2%, respectively. Based on the 
original pathologic grade, slides were 3% WD, 54% MD, and 43% PD (Table 2).
Overall, the IOR for H&E diagnoses for the entire 2004-WHO classification system (44DC), 
was κ = 0.25 (95% CI, 0.23–0.26) (Figure 1; Table 3). The 44DC κ statistics improved with 
simplification into 10DC (overall κ = 0.48), and again into the SC/non-SC classes (overall κ 
= 0.55; 95% CI, 0.53–0.58) and into the AD/non-AD classes (overall κ = 0.59; 95% CI, 
0.57–0.61). Table 3 shows the variability of IOR as a function of diagnostic confidence, 
pulmonary pathology expertise, and neoplastic grade. The IOR varied most widely as a 
function of the pathologist’s confidence in his or her H&E diagnosis. For each classification 
and level of expertise, IOR was higher when diagnostic confidence was higher. Overall, IOR 
improved by simplifying 44DC (high confidence κ = 0.38, moderate confidence κ = 0.15) 
into 10DC (high confidence κ = 0.69, moderate confidence κ = 0.31) and again into SC/non-
SC classes (high confidence κ = 0.78, moderate confidence κ = 0.28).
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For each classification (44DC, 10DC, dichotomous), IOR was higher when pulmonary 
pathology expertise was higher (Table 3). The IOR improved by simplifying the 
classification from 44DC (expert κ = 0.30, community κ = 0.19) into 10DC (expert κ = 
0.55, community κ = 0.36), and again into SC/non-SC classes (expert κ = 0.64, community 
κ = 0.41) and AD/non-AD classes (expert κ = 0.69, community κ = 0.46).
For each classification (44DC, 10DC, dichotomous), IOR was higher when carcinomas were 
better differentiated (Table 3). The IOR improved by simplifying the 44DC (WD/MD κ = 
0.27; PD κ = 0.22) into 10DC (WD/MD κ = 0.52; PD κ = 0.41) and again into the SC/non-
SC (WD/MD κ = 0.60; PD κ = 0.46) and AD/non-AD (WD/MD κ = 0.64; PD κ = 0.48) 
classes. When considering only the 3 WD slides (all non-SC), pathologists were in 100% 
diagnostic agreement.
Mean agreement of each study pathologist’s diagnosis with the original pathologist’s 
diagnosis (κ = 0.52) was comparable to the overall IOR for 10DC of κ = 0.48. To assess the 
effect of potential outliers, study pathologist-pairs were stratified by pairwise agreement 
quartiles. The top quartile approached the goal of κ = 0.70 for good clinical agreement, 
whereas the bottom quartile had fair agreement. We identified both expert and community 
pathologists in all agreement quartiles (data not shown).
Tumor, slide, and pathologist variables were evaluated for univariable and multivariable 
effect on SC/non-SC IOR (Table 4). All univariable and all but one multivariable predictor 
(cumulative pathologist experience) were statistically significant. Predictors for higher IOR 
included better-differentiated carcinomas, better slide quality, and higher diagnostic 
confidence. Pathologist diagnostic confidence was statistically associated with neoplastic 
grade, slide quality, experience, and expertise. Because confidence was highly associated 
with the perception of slide quality (P < .001), any effect of slide quality on interpretation is 
probably reflected in the data regarding diagnostic confidence.
Increasing difference in years of pathologist practice experience predicted decreased IOR. 
Roughly, a 10% decrease in agreement was found for every 5 years difference in practice 
experience. Increased cumulative pathologist practice experience predicted increased IOR, 
statistically significant by univariate analysis only, with a 3% increase in agreement for 
every 5 years of cumulative practice experience. Pulmonary pathology expertise in both 
pathologists of a pair predicted an increased IOR: expert pathologist-pairs had a 38% 
increase in the odds of agreement compared with community pathologist pairs. Pulmonary 
pathology expertise was highly correlated with confidence, such that the odds of agreement 
for expert pathologist-pairs showed a 21% increase after controlling for confidence, quality, 
and grade in multivariable analysis (Table 4). Figure 2 graphically summarizes many of the 
results. Some cases, particularly WD cases of SC and AD, were readily identified with high 
IOR by H&E alone.
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Strengths of the Study
Non–small cell lung carcinoma subtyping has refined and improved survival of patients with 
advanced NSCLC.2,32 We designed a comprehensive prospective study of H&E diagnostic 
agreement for NSCLC. Using the 2004-WHO, our data measure IOR for the entire 44DC 
and provide estimates for the parent 10DC and the therapeutically relevant SC/ non-SC 
classes (Table 1). These data evaluate factors that might predict IOR, including sums and 
differences in years of practice experience, expertise in lung pathology, slide quality, 
diagnostic confidence, and carcinoma grade.
We hypothesized that IOR for the H&E diagnosis of NSCLC subtypes according to the 
2004-WHO would show a κ of 0.7, an agreed-upon, albeit arbitrary, target for minimal 
clinical test reproducibility. We found that overall IOR among study pathologists was fair (κ 
= 0.25) when using all 44DC, with improvement following collapse into the 10DC (κ = 
0.48) or the therapeutically relevant SC/non-SC classes (κ = 0.55) (Table 3). The low κ for 
44DC is not surprising because many of these diagnoses would not be made in practice 
without ancillary stains. Our 10DC IOR results appear similar in magnitude to studies of 
prior versions of the classification,12,13,15,16,18–22,24 but direct comparison to historic studies 
is limited because the most methodologically similar study12,13 used bronchial biopsies 
rather than resection specimens. Additionally, other studies used glass slides and simplified 
the classification system into major diagnostic categories rather than using the 
comprehensive diagnostic listings.
Our multivariate analysis shows that grade, slide quality, diagnostic confidence, difference in 
experience, and pulmonary pathology expertise are independent predictors of NSCLC H&E 
diagnostic agreement, although those methods do not account for the dependencies among 
the slide review. Controllable factors that may improve agreement include optimizing H&E 
slide quality and increasing lung pathology expertise.
Our data suggest an upper limit for IOR by H&E alone, mainly because of PD NSCLC 
lacking morphologic features of SC or AD.19 Pathologist confidence in his or her H&E slide 
diagnosis, the most predictive factor for increased IOR, likely reflects a qualitative 
amalgamation of grade, slide quality, and expertise. Diagnostic agreement may improve with 
systematic definition and application of reflex stain panels for PD NSCLC. Providing 
histochemical (eg, mucin) and immunohistochemical (eg, thyroid transcription factor 1, p63, 
cytokeratin 5/6, and napsin A) phenotypes, as well as cytogenetic tests (echinoderm 
microtubule-associated proteinlike 4 [EML4]– anaplastic lymphoma kinase [ALK] 
translocation) and molecular tests (eg, EGFR/KRAS/BRAF mutations) to define molecular 
targets for therapy likely would have improved diagnostic agreement; this is an important 
question for follow-up studies.
The 2004-WHO continues to reward the lung cancer community with meaningful 
associations, such as EGFR mutations with AD,33 and the EML4-ALK fusion oncogene 
with signet-ring histology.34 The goal remains to incrementally improve diagnostic 
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classifications, criteria, and reflex ancillary tests to optimize agreement, as well as to report 
associated prognostic and predictive data to guide patient management.
Although detailed classification likely reflects underlying biology, κ statistics increase with 
a reduced number of classes; therefore, simplifying the morphologic classification should 
improve agreement. Pathology reports that include both the specific (44DC) diagnosis and 
parent (10DC) category may reduce confusion by treating clinicians regarding management 
of uncommon WHO diagnoses.
Potential Limitations
Although our data include 7130 slide-pairs drawn from an incident patient series of 96 cases, 
we recognize that the sample size was insufficient to represent all diagnostic entities in the 
2004-WHO. Diagnoses were based on single H&E images, rather than complete cases (glass 
slides with ancillary stains), with a goal of establishing baseline κ statistics for the H&E 
diagnosis of NSCLC. Based on feedback from several pathologists at the time the study was 
designed, we determined that reviewing 48 to 96 entire cases would deter participation. 
Study pathologists’ agreement with each other was similar to their agreement with the 
original pathology diagnosis, arguing that our study design reflects what would have been 
observed if the entire case had been reviewed. We intentionally provided only H&E sections, 
without pertinent clinical, radiographic, or ancillary stain data, other than the knowledge that 
the patient carried a diagnosis of NSCLC, to estimate IOR of 3 relevant NSCLC 
classifications (44DC, 10DC, SC/non-SC) under conditions in which each pathologist had 
exactly the same information: an H&E image only.
Several pathologists lacked familiarity with digital images or had concerns regarding image 
resolution, which may have compromised their diagnostic abilities. However, digital images 
control for any variation in the circulated images, a major advantage over the morphologic 
variation inevitable in 24 recut sections through a paraffin block. Although not readily 
employed in clinical practice, it is commonly used in teaching and research, including for 
The Cancer Genome Atlas.35 Wider use of digital slides could facilitate timely accrual to 
trials requiring central pathology review and expedite expert review of challenging cases.
The IOR was similar among pathologists who primarily used DVDs versus jpegs or both 
(regardless of the 6 cases with nonrepresentative, high-power jpeg images). These data argue 
that IOR estimates were not affected by pathologist decision to use snapshots versus DVD 
images, or by the 6% of cases with nonrepresentative ×20 snapshots.
Our resected specimen results may be extrapolated to, but may not fully represent, small 
biopsies and fine-needle aspirates from patients with advanced NSCLC. Recently, the 
International Association for the Study of Lung Cancer/American Thoracic Society/
European Respiratory Society36 published major changes in the lung AD subclassification, 
including guidelines for small-biopsy diagnosis, although those changes do not alter the 
distinction among the major 10DC subtypes, such as SC and AD.
The SC/non-SC categorization is not a feature of the WHO classification but, rather, was 
based on clinical and regulatory practice: pemetrexed has no proven efficacy in SC in any of 
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3 pivotal studies2,37,38 contributing to the drug’s approval in non-SC histology NSCLC, and 
bevacizumab is contraindicated in SC because of potential life-threatening hemorrhage.1 
Our study was executed in 2008, before the publication of pivotal studies related to 
pemetrexed and bevacizumab in journals not directed at pathologists. Nevertheless, we 
demonstrate that even a simple classification, such as SC/non-SC, is imperfect by H&E 
alone (SC/non-SC, experts, maximum κ = 0.84).
CONCLUSIONS
Management of advanced NSCLC is now critically dependent on precise histologic 
diagnoses. This study provides baseline estimates of the IOR for H&E diagnosis of NSCLC 
and shows that agreement is a function of pathologist experience, pulmonary pathology 
expertise, pathologist diagnostic confidence, slide quality, and carcinoma grade. Strict 
definition and application of diagnostic criteria may incrementally improve IOR for H&E 
diagnosis of NSCLC, but major improvements in NSCLC IOR will likely depend on 
systematic integration of validated histochemical, immunohistochemical, and molecular 
methods. We recommend reporting the major (10DC) diagnostic category along with the 
specific (44DC) WHO diagnosis, thereby providing the groundwork for further therapeutic 
advances while reducing the potential for clinical confusion in how to manage unusual 
NSCLC cases. Our findings define a baseline measure for NSCLC H&E diagnostic 
agreement, to which future studies determining incremental benefits of reflex ancillary tests 
at the protein, cytogenetic, and molecular levels may be compared.
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Pathologist agreement for hematoxylin-eosin diagnosis of squamous versus non-squamous 
carcinoma. Abbreviations: All, all participant pathologists; Q1, first quartile; Q2, second 
quartile; Q3, third quartile; Q4, fourth quartile.
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Each column of the figure corresponds to 1 of the 96 hematoxylin-eosin (H&E) slides. The 
top row shows study pathologist consensus (the majority) diagnosis. Average confidence and 
request for immunohistochemical stains across all reviewers are plotted as a function of the 
slides. Diagnosis distribution represents a heat map of the fraction of times any given 10 
diagnostic-class (10DC) diagnosis was made for each of the 96 slides. The bottom 2 rows 
show the original pathologic diagnosis and the original neoplastic grade.
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Table 1
Adaptation of the World Health Organization (4th ed) Classification Systema and Corresponding Simplified 
10- and 2-Class Systems
44 Diagnostic Categories 10 Diagnostic Categories Therapeutically Relevant 
2 Classes: SC/Non-SC
MALIGNANT EPITHELIAL TUMORS





Small cell carcinoma Small cell carcinoma Nonsquamous carcinoma 
(other NSCLC)
 Combined small cell carcinoma
Adenocarcinoma Adenocarcinoma






  Mixed nonmucinous and mucinous or indeterminate
  Solid adenocarcinoma with mucin production
  Fetal adenocarcinoma
  Mucinous (“colloid”) carcinoma/mucinous cystadenocarcinoma
  Signet-ring adenocarcinoma
  Clear cell adenocarcinoma
Large cell carcinoma Large cell carcinoma
 Large cell neuroendocrine carcinoma
 Combined large cell neuroendocrine carcinoma
 Basaloid carcinoma
 Lymphoepithelioma-like carcinoma
 Clear cell carcinoma
 Large cell carcinoma with rhabdoid phenotype
Adenosquamous carcinoma Adenosquamous carcinoma
Sarcomatoid carcinoma Sarcomatoid carcinoma
 Pleomorphic carcinoma
 Spindle cell carcinoma
 Giant cell carcinoma
 Carcinosarcoma
 Pulmonary blastoma
Carcinoid tumor Carcinoid tumor Other carcinomas
 Typical carcinoid
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44 Diagnostic Categories 10 Diagnostic Categories Therapeutically Relevant 
2 Classes: SC/Non-SC
 Atypical carcinoid
Salivary gland tumors Salivary gland tumor
 Mucoepidermoid carcinoma
 Adenoid cystic carcinoma
 Epithelial-myoepithelial carcinoma
MISCELLANEOUS TUMORSb (including mesenchymal tumors and 
lymphoproliferative tumors)
Miscellaneous tumorsb
METASTATIC TUMORS Metastatic tumors
Abbreviations: SC/non-SC, squamous versus nonsquamous carcinoma; NSCLC, non–small cell lung cancer.
a
Data derived from Travis et al,7 2004.
b
Modified: Mesenchymal tumors and lymphoproliferative tumors were added to miscellaneous category. Omitted: preinvasive lesions, benign 
epithelial tumors.
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Table 2
Study Participant, Methodology, and Diagnosis Demographics and Statistics
Characteristics of the Study Participants
Characteristics of the Pathologists Demographics, No. (%)
Total number of participants/total approached 24/26 (92)
Sex, M     18 (75)
Surgical pathology fellowship, yes     16 (67)
Expert lung pathologist, yes     12 (50)
Years of experience:
 Minimum 1
 Median 17  
 Maximum 36  
Quality Assessment of Study Methodology
Characteristics of the H&E Slides Frequency, %
Slide of sufficient quality, yes 91
Confidence in assigned diagnosis:
 High 52
 Moderate 40
 Low   8
Request for special stains, yes 10
Distribution of Morphologic Diagnoses
Morphology Original Diagnosis, % Study Diagnosis, %
Squamous cell 35% 36%
Adenocarcinoma 35% 31%
Adenosquamous   13     3
Large cell     9   17
Miscellaneousa     6     7
Sarcomatoid carcinoma     1     4
Carcinoid     1     2
Original Pathologic Grade Assigned to Study H&E Slides
Original Pathologic Grade Results, %
Not poorly differentiated: 57
 Well differentiated   3




Category includes adenoid cystic, mucoepidermoid, spindle cell, basaloid non–small cell lung carcinoma, and malignant mesothelioma.
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Table 4
Univariable and Multivariable Predictors of Interobserver Reproducibility in the Hematoxylin-Eosin (H&E) 





Predictors, OR (95% 
CI) Interpretation
Tumor factors
 Gradea 0.722 (0.646–0.808) 0.812 (0.714–0.922) Decreased agreement in more-poorly 
differentiated tumors
H&E slide factors
 Qualityb 0.573 (0.494–0.665) 0.689 (0.576–0.823) Decreased agreement if one or both 
pathologists felt the slide was of low quality
Confidencec 2.21 (1.86–2.63) 2.02 (1.68–2.41) Increased agreement if both pathologists 
were highly confident
Pathologist factors
 Difference in pathologist experienced 0.904 (0.864–0.945) 0.901 (0.860–0.944) For every 5 y in experience difference, there 
is a 10% decrease in the odds of agreement
 Cumulative pathologist experiencee 1.03 (1.01–1.07) 1.03 (1.00–1.06) For every 5 y of combined experience, there 
is a 3% increase in the odds of agreement
 Pulmonary pathology expertf 1.38 (1.21–1.58) 1.21 (1.04–1.41) Increased agreement if both are expert
Abbreviations: CI, confidence interval; H&E, hematoxylin-eosin; OR, odds ratio.
a
Grade based on the original pathologic diagnosis (well-differentiated, < moderately differentiated, < poorly differentiated); the OR for 1 unit 
increase in grade.
b
The OR comparing cases where one or more pathologists felt the quality of slide was insufficient to cases where both felt the quality was 
sufficient.
c
The OR comparing cases where both pathologists had high confidence to any other confidence pairing.
d
The OR for difference in experience between the pathologists per 5-year block.
e
The OR for combined sum of experience for the pathologist pair per 5-year block.
f
The OR comparing cases where both pathologists were experts compared with neither being expert.
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